Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01887288 · ClinicalTrials.gov registry record · Phase 2
Capecitabine With Digoxin for Metastatic Breast Cancer
A Phase 2 study, sponsored by Western Regional Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01887288: Clinical Trial Phase 2 study, sponsored by Western Regional Medical Center.
NCT01887288 is a Phase 2 study that was terminated before completion, run by Western Regional Medical Center. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01887288, a Phase 2 study, was terminated before completion, sponsored by Western Regional Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
To evaluate the Growth Modulation Index (GMI) of the combination of metronomic capecitabine with oral digoxin in metastatic breast cancer
Interventions
- DRUG Capecitabine
- DRUG Digoxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01887288
The ClinicalTrials.gov registry entry for NCT01887288 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Western Regional Medical Center, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capecitabine is the first listed.
NCT01887288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01887288 about?
NCT01887288 is a clinical study titled "Capecitabine With Digoxin for Metastatic Breast Cancer". To evaluate the Growth Modulation Index (GMI) of the combination of metronomic capecitabine with oral digoxin in metastatic breast cancer
What is the current status of trial NCT01887288?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2013-04. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01887288?
The interventions under investigation include: Capecitabine (DRUG), Digoxin (DRUG).
Who is sponsoring clinical trial NCT01887288?
This trial is sponsored by Western Regional Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.